Aptose Biosciences is a clinical-stage oncology company pioneering targeted therapies and companion diagnostics that offer a new approach to inducing apoptosis (programmed cell death) and personalized treatment strategies for patients with life-threatening cancers.  Aptose emerged in August 2014 with the decision to establish a new corporate foundation, applying fresh scientific insights and resources to the advancement of key assets. Under the executive leadership of Dr. William G. Rice and Gregory Chow, Aptose’s mission is driven by scientific vision and clinical acumen, and supported by a distinguished clinical development team and advisors.